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Edited by Barry HalliwellAbstract Exposure of a-synuclein (aS), a major component of
Lewy bodies in Parkinsons disease, to polyunsaturated fatty
acids (PUFAs) triggers the formation of soluble aS oligomers.
Here, we demonstrate that PUFA binds recombinant aS protein
through its N-terminal region (residues 2–60). In HEK293 cells,
aS mutants lacking the N-terminal region failed to form oligo-
mers in the presence of PUFA. The PUFA-induced aS oligomer-
ization was accelerated by C-terminal truncation or Ser129
phosphorylation of aS; however, this eﬀect was abolished by
deletion of the N-terminus. The results indicate that the N-termi-
nus of aS is essential for the PUFA-induced aS oligomerization.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Parkinsons disease (PD) is characterized by the progressive
degeneration of dopaminergic neurons in the substantia nigra
and the presence of intracytoplasmic ﬁlamentous inclusions
called Lewy bodies (LBs) and Lewy neurites (LNs). Identiﬁca-
tion of missense mutations in the a-Synuclein (aS) gene (A30P,
A53T, and E46K) [1–3] and the multiplication [4] of the locus
in autosomal-dominant familial PD indicates a direct link of
aS to the pathogenesis of familial PD. aS is also thought to
play a critical role in sporadic cases of PD, because ﬁbrillized
aS is a major component of LBs and LNs [5]. In vitro experi-
ments have shown that aS readily oligomerizes into ﬁbrils that
share ultrastructural features of ﬁbrils in LBs [6]. Furthermore,
overexpression of human wild-type [7] or A53T [8,9] aS in
transgenic mice results in motor impairment with the develop-Abbreviations: PD, Parkinsons disease; aS, alpha-synuclein; LB, Lewy
body; LN, Lewy neurite; FA, fatty acid; PUFA, polyunsaturated fatty
acid; FABP, fatty acid-binding protein; OA, Oleic acid; ALA, a-
linolenic acid; GRK, G protein-coupled receptor kinase; NAC, non-
amyloid b-protein component
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doi:10.1016/j.febslet.2008.10.001ment of aS inclusions. Feany and colleagues have also re-
ported that overexpression of wild-type, A30P or A53T-aS in
Drosophila shows loss of dopaminergic neurons with an in-
crease in ﬁlamentous aS inclusions [10]. Accumulated evidence
suggests that the oligomerization of aS into ﬁbrils aﬀects the
toxicity of the molecule [11]. Previous studies have demon-
strated that the oligomerization of aS is accelerated by oxida-
tion and nitration of aS [12], phosphorylation of aS at Ser129
[13,14], C-terminal truncation of aS [15] or binding of phos-
pholipids to aS [16]. However, the exact biochemical mecha-
nisms for the formation of pathological aS oligomers remain
to be elucidated.
Sharon et al. reported that the N-terminus (residues 2–19)
and the C-terminus (residues 123–140) of aS have homology
to the fatty acid (FA)-binding motif of fatty acid-binding pro-
tein (FABP) [17]. They also showed that recombinant aS di-
rectly binds to FA in a stochiometric manner, and that
soluble, lipid-associated monomers and oligomers of aS are
present in transgenic mouse brains expressing wild-type or
A53T-aS [17,18]. On the basis of the facts, they concluded that
aS has the properties of FABP [17,18]. They further demon-
strated that exposure of monomeric aS to polyunsaturated
fatty acids (PUFAs) promotes the formation of soluble aS
oligomers in cultured mesencephalic cells [18]. In the brains
of PD and dementia with Lewy bodies, the amount of soluble,
lipid-associated aS oligomers increased [18]. Since the soluble
aS oligomers seem to be precursors of ﬁbrils [11], the ﬁndings
suggest that the binding of aS to PUFA is one of the key
events in the process for conversion from soluble monomers
to pathological oligomers of aS.
The present study was carried out to determine the aS region
responsible for the binding to FA by using a series of aS dele-
tion mutants, and to assess a role of the binding of aS to
PUFA in the oligomerization of aS. The results show that
the binding of aS to PUFA in its N-terminal region is essential
for the PUFA-induced oligomerization of aS.2. Materials and methods
2.1. Plasmid construction
Wild-type human aS (Wt-aS) cDNA and human G protein-coupled
receptor kinase 5 (GRK5) cDNA were cloned into the pcDNA3.1 vec-
tor (Invitrogen) [14]. aS deletion mutant cDNAs and aS familial PD-
linked mutant (A30T, E46K and A53T) cDNAs were generated by the
two-step PCR mutagenesis method. Nucleotide sequences of all con-
structs were conﬁrmed.blished by Elsevier B.V. All rights reserved.
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Wild-type and deletion mutants of human aS cDNAs were cloned
into the pGEX-4T-1 vector (GE Healthcare) to generate glutathione
S-transferase fusion protein. The fusion proteins were expressed in
Escherichia coli. Recombinant aS was puriﬁed from the fusion protein
by the method described previously [14].
2.3. Oleic acid (OA)-binding assay
OA-binding assay was carried out as previously described with
slight modiﬁcations [17,19]. Hydroxyalkoxypropyl-Dextran type IV
(known as Lipidex 1000, Sigma) was known to bind to free FA at
0–4 C and FA-bound proteins at 37 C [19]. To collect FA-unbound
proteins, recombinant aS proteins puriﬁed from E. coli were incu-
bated for 30 min with 5% Lipidex 1000 at 37 C. After centrifugation
at 20000 · g for 5 min, the supernatant containing FA-unbound aS
was recovered and stored at 80 C. To determine the binding of
aS to OA, 5 lM aS protein was incubated with various amounts of
[14C] OA (Moravek Biochemicals, 54 mCi/mmol) in 100 ll of phos-
phate-buﬀered saline (PBS; 100 mM phosphate, pH 7.4, 150 mM
NaCl) for 1 h at room temperature. The mixture was kept on ice
for 10 min, and 10 ll of 50% (v/v) Lipidex 1000 was added. The mix-
ture was incubated for 10 min on ice. After centrifugation at
15000 · g for 5 min, protein-bound [14C] OA in the supernatant
was measured by scintillation counting.
2.4. In vitro oligomerization of aS
One micromolar recombinant aS proteins in PBS were incubated at
37 C for 12 h with or without a-linolenic acid (ALA, Sigma) of indi-
cated concentrations [14]. Samples (100 ng protein) were analyzed by
immunoblotting using anti-aS monoclonal antibody (Syn-1, which rec-
ognizes residues 91–99 of human aS; BD Transduction Laboratories)
[20].
2.5. Cell culture and transfection
Human embryonic kidney (HEK) 293 cells were maintained in Dul-
beccos modiﬁed Eagles medium (Invitrogen) supplemented with 10%
fetal bovine serum. HEK293 cells were transfected with aS cDNAs
using Lipofectamine Plus reagents (Invitrogen), according to the man-
ufacturers protocol.
2.6. PUFA-induced aS oligomerization in the cells
For the PUFA-induced aS oligomerization, the transfectants
were recovered at 32 h after transfection, and the cells were fur-
ther incubated with serum-free medium containing 500 lM ALA
and 100 lM FA-free bovine serum albumin (BSA, Sigma) for
16 h [14,18].
2.7. PUFA-induced oligomerization of phosphorylated aS in the cells
HEK293 cells were transiently co-transfected with GRK5 cDNA
and either wild-type or mutant aS cDNA [14]. Twenty-four hours after
the transfection, 20 nM okadaic acid (Wako) was added to the culture
and the cells were incubated for 16 h. The cells were further incubated
for 9 h in fresh serum-free medium containing ALA/BSA complexes
and okadaic acid and the cell lystaes were analyzed by immunoblotting
[14].Fig. 1. aS deletion mutants. (A) Schematic diagrams of wild-type aS
(Wt-aS) and aS deletion mutants. (B) The purity and electrophoretic
pattern of recombinant aS mutants. Recombinant proteins (2 lg) were
analyzed by SDS–PAGE using 15% polyacrylamide gel. The gel was
stained with Coomassie brilliant blue R-250. (C) Recombinant aS
proteins (100 ng) were loaded to the 12.5% polyacrylamide gel and
analyzed by immunoblotting using three diﬀerent monoclonal anti-
bodies. Monoclonal antibodies Syn-1, LB509 and 211 recognize
residues 91–95, 115–122 and 121–125, respectively.2.8. Protein fractionation and immunoblotting
Transfectants of HEK293 cells were suspended in homogenization
buﬀer [20 mM HEPES, pH 7.4, 1 mM MgCl2, 0.32 M sucrose,
43 mM 2-mercaptoethanol, 1 · protease inhibitor cocktail (RocheDi-
agnostic), 20 mM NaF, 1 mM Na3VO4] and were disrupted by brief
sonication [14,17]. Samples were sequentially centrifuged at 8000 · g
for 15 min and at 370000 · g for 1 h. The resultant supernatant was
recovered and stored as the cytosol fraction. The post-370000 · g pel-
let was disrupted by sonication in homogenization buﬀer containing
1% Nonidet P-40, 1% sodium deoxycholate and 0.1% SDS, and the
homogenates were incubated on ice for 30 min. After centrifugation
at 12000 · g for 30 min, the supernatant was stored as the pellet frac-
tion. Since the detection of lipid-associated aS oligomers by immuno-
blotting requires delipidation procedures, we treated the cytosol
fractions at 60 C for 16 h for delipidation prior to gel-loading. The ef-
fect of the delipidation for detection of aS oligomers was described
previously [14,17,18].Protein samples were denatured by boiling for 5 min in Laemmlis
sample buﬀer containing 2.5% 2-mercaptoethanol. Immunoblotting
was performed as described previously [14]. The transferred membrane
was probed with the antibodies as follows: aS speciﬁc, Syn-1, LB509
(monoclonal IgG, which recognizes residues 115–122 of aS; Zymed)
[21] and 211 (monoclonal IgG, which recognizes residues 121–125 of
aS; Sigma) [22]; phosphorylated aS at Ser129 speciﬁc, psyn#64 (mono-
clonal IgG; Wako) [23]; b-actin (Sigma); or superoxide dismutase 1
(SOD1, Stressgen). Bands were visualized by enhanced chemilumines-
cence (ECL) or ECL plus (GE Healthcare). Relative intensities of de-
tected bands were scanned and quantiﬁed with NIH Image J, version
1.33 or Quantity one (Bio-Rad) software.
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3.1. Mapping of the FA-binding region of aS
To determine the FA-binding region(s) in the aS molecules,
we prepared recombinant wild-type and four deletion mutants
of aS protein (Fig. 1A). The ﬁrst mutant lacks the N-terminal
region homologous to the FA-binding motif of FABP (DN-aS,
residues 2–19) [17]. The second mutant lacks the region be-
tween the N-terminal homologous region and the non-amyloid
b-protein component (NAC) (D20–60-aS, residues 20–60). The
third mutant lacks the ﬁbrillization core of the NAC (DM-aS,Fig. 2. Analysis of the FA-binding region of aS. Puriﬁed aS protein (5 lM)
[14C] OA was separated from free [14C] OA by using Lipidex 1000 (see Sectiresidues 73–83) [24]. The forth mutant lacks the C-terminal re-
gion homologous to the FA-binding motif of FABP (DC-aS,
residues 123–140) [17] (Fig. 1A). Purity of the recombinant
proteins was >95%, as determined by SDS–PAGE (Fig. 1B).
As shown in Fig. 1B, the mobilities of DN-aS, D20–60-aS
and DM-aS monomers corresponded to those expected from
the length of deleted amino acids, however, DC-aS migrated
much faster than the position predicted from its molecular size.
We could not elucidate the reason why DC-aS had high elec-
trophoretic mobility. To conﬁrm the amino acid sequence
lacking in the product of DC-aS, we performed immunoblotswas incubated with [14C] OA of various concentrations. Protein-bound
on 2). Data points represent means ± S.D. (n = 3).
Fig. 3. Analysis of the aS region required for PUFA-induced
oligomerization. (A) aS deletion mutants diﬀerentially aﬀect ALA-
induced aS oligomerization. HEK293 cells expressing either wild-type
aS or one of the deletion mutants were incubated for 16 h in serum-free
medium containing BSA (100 lM) or ALA/BSA complexes (500/
100 lM). Cytosol fractions (30 lg protein) were heat-treated as
described in the Materials and methods and analyzed by immuno-
blotting. aS oligomers from ALA-treated recombinant aS protein
(Rec.) are also shown. The asterisk indicates the interface of resolving
and stacking gels; the arrowhead points to a non-speciﬁc band
(47 kDa) by Syn-1 antibody. For loading control, same amounts of
non-heat-treated samples were immunoblotted with anti-b-actin and
anti-SOD1 antibodies. (B) Distribution of aS proteins in cytosol and
pellet fractions. HEK293 cells expressing either wild-type aS or one of
the deletion mutants were incubated for 16 h in serum-free medium
containing ALA/BSA complexes. Cytosol fractions (20 lg protein,
lanes C) and pellet fractions (20 lg protein, lanes P) were heat-treated
and analyzed by immunoblotting. For loading control, same amounts
of non-heat-treated samples were immunoblotted with anti-SOD1
Fig. 4. The N-terminal FA-binding region is required for the
accelerating eﬀect of C-terminally truncated aS on the PUFA-induced
oligomerization. HEK293 cells expressing either DC-aS (lacking
residues 123–140) or DN+C-aS (lacking residues 2–19 and 123–140)
were incubated for 16 h in serum-free medium containing BSA
(100 lM) or ALA/BSA complexes (500/100 lM). Cytosol fractions
(30 lg protein) were heat-treated and analyzed by immunoblotting
with Syn-1. For loading control, same amounts of non-heat-treated
samples were immunoblotted with anti-b-actin and anti-SOD1 anti-
bodies. The asterisk indicates the interface of resolving and stacking
gels; the arrowhead points to the non-speciﬁc band by Syn-1.
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residues 121–125 and 115–122 of aS, respectively. As expected,
the product of DC-aS reacted with LB509, but not with 211
(Fig. 1C and Supplemental Fig. 1).
We determined the binding of [14C] OA to the deletion
mutants by the Lipidex assay [17,19]. Dose-dependent binding
of [14C] OA was observed when a constant amount (5 lM) of
puriﬁed recombinant Wt-aS was incubated with [14C] OA of
various concentrations (10–70 lM) (Fig. 2). Among the
deletion mutants, both DM-aS and DC-aS bound OA in a
dose-dependent manner. In contrast, both DN-aS and D20–
60-aS failed to bind a signiﬁcant amount of [14C] OA under
the same experimental conditions (Fig. 2).
3.2. Role of the FA-binding region of aS in the PUFA-induced
oligomerization
In order to determine whether the binding of PUFA to aS
enhances the oligomerization of aS, we assessed the formation
of soluble oligomers in the cells transfected with one of the
deletion mutants in the presence or absence of ALA. In the
cytosol fraction of the cells expressing Wt-aS, DM-aS, orantibody. (C) Quantitative analysis of PUFA-induced aS oligomeri-
zation in deletion mutants. Relative ratio of the band intensity of
oligomers (subtracting the non-speciﬁc 47 kDa band from total
oligomers above 37 kDa) to that of monomers is shown. Data
represent means ± S.D. (n = 5 Wt-aS, DM-aS, and DC-aS; n = 3
DM-aS). The P-values were estimated by ANOVA with post hoc
Scheﬀe test.
b
Fig. 5. The N-terminal FA-binding region is required for the accelerating eﬀect of phosphorylation of Ser129 in aS on the PUFA-induced
oligomerization. (A) HEK293 cells co-expressing aS and either chloramphenicol acetyltransferase (CAT) or GRK5 were incubated for 9 h in serum-
free medium containing ALA/BSA complexes (500/100 lM) with or without 20 nM okadaic acid. Cytosol fractions (30 lg protein) were heat-treated
and analyzed by immunoblotting with Syn-1 and psyn#64. (B) Cells co-expressing GRK5 and each of the deletion mutants were incubated for 9 h in
serum-free medium containing ALA/BSA complexes (500/100 lM) and 20 nM okadaic acid. Cytosol fractions (30 lg protein) were heat-treated and
analyzed by immunoblotting with Syn-1. For loading control, same amounts of non-heat-treated samples were immunoblotted with anti-b-actin and
anti-SOD1 antibodies. Asterisks indicate the interface of resolving and stacking gels; arrowheads point to the non-speciﬁc band by Syn-1. (C)
Relative ratio of band intensity of oligomers to that of monomers is shown. Data points represent means ± S.D. (n = 6). The P-values were estimated
by ANOVA with post hoc Scheﬀe test.
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the treatment with ALA (Fig. 3A). The size distribution of
the oligomers of wild-type aS formed by the ALA treatmentwas comparable to that of recombinant aS oligomers
(Fig. 3A). As reported by Sharon et al. [18], smear pattern in
the background and gel-excluded immunoreactive material
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ALA treatment. The smear pattern may represent aggregated
aS that is partially SDS-soluble. The gel-excluded material
may represent the species that are SDS-insoluble. In the cyto-
sol fractions of the cells expressing DM-aS or DC-aS, the
smear pattern and gel-excluded material were also observed.
In the cytosol fractions of the cells expressing either DN-aS
or D20–60-aS, however, none of the aS oligomers, smear pat-
tern nor gel-excluded material was formed in the presence of
ALA (Fig. 3A). The expression of DN-aS and D20–60-aS
was lower than that of the other counterparts. To exclude
the possibility that the N-terminal truncation of DN-aS and
D20–60-aS resulted in the formation of insoluble proteins,
we assessed whether or not the products of the mutants were
present in the pellet fractions of ALA-treated cells. In the pellet
fraction of the cells expressing either Wt-aS, DM-aS, or DC-
aS, small amounts of aS monomers, but none of the aS oligo-
mers, smear pattern nor gel-excluded material, were detectable
(Fig. 3B). In the pellet fraction of the cells expressing either
DN-aS or D20–60-aS, neither the aS monomer nor oligomer
was detectable (Fig. 3B). To correct the diﬀerence in expression
levels of aS among the transfectants in the cytosol fractions,
we determined the relative ratio of the band intensity of the
oligomers to that of monomers. The proportion of the soluble
oligomers of DN-aS or D20–60-aS to the monomers in the
presence of ALA was lower than the proportion of the oligo-
mers of Wt-aS (Fig. 3C).
In the cells overexpressing Wt-aS, DM-aS, or DC-aS, the aS
monomer in the cytosol fractions markedly increased after
exposure to ALA (Fig. 3A). The same phenomenon has been
previously described [18]. Apparent increase in the monomers
of aS after the PUFA treatment was speculated to be due to
conformational changes of the molecules that enhance anti-
body recognition [18].
In order to assess whether the binding of PUFA to aS in-
duces the aS oligomerization, each of the recombinant proteins
of wild-type and deletion mutants was incubated with ALA for
12 h at 37 C. Analysis of recombinant Wt-aS, DM-aS, or DC-
aS after incubation with ALA showed that ALA enhanced the
formation of oligomers (Supplemental Fig. 2). It was noted
that the proportion of oligomers of DN-aS or D20–60-aS
was signiﬁcantly lower than that of Wt-aS (Supplemental
Fig. 2).Fig. 6. The eﬀect of familial PD-linked mutations of aS on the PUFA-
induced oligomerization of aS. (A) HEK293 cells expressing either Wt-
aS, A30P-aS, E46K-aS, or A53T-aS were incubated for 8 h in the
presence or absence of ALA/BSA complexes (500/100 lM). Cytosol
fractions (30 lg protein) were heat-treated and analyzed by immuno-
blotting with Syn-1. For loading control, same amounts of non-heat-
treated samples were immunoblotted with the anti-SOD1 antibody.
Asterisks indicate the interface of resolving and stacking gels;
arrowheads point to the non-speciﬁc band by Syn-1. (B) Relative
ratio of band intensity of oligomers to that of monomers is shown.
Data represent means ± S.D. (n = 5). The P-values were estimated by
ANOVA with post hoc Scheﬀe test.3.3. Requirement of the FA-binding region for the acceleration of
aS oligomerization by C-terminal truncation and
phosphorylation of Ser129
As shown in Fig. 3A and C, DC-aS formed higher levels of
soluble oligomers in the presence of ALA than Wt-aS, indicat-
ing that the C-terminal truncation of aS accelerated the forma-
tion of oligomers in the presence of PUFA. To investigate
possible roles of the C-terminal region of aS in the PUFA-in-
duced oligomerization, we determined the oligomerization of
the deletion mutant which lacks both the N-terminal and C-
terminal regions (DN+C-aS, lacking residues 2–19 and 123–
140, Supplemental Fig. 1). The cells expressing DN+C-aS
failed to form soluble aS oligomers in the presence of ALA,
although comparable amounts of aS monomers were found
in the DN+C-aS and the DC-aS mutants (Fig. 4).
As described in our previous report [14], co-overexpression
of aS and GRK5 in HEK293 cells in the presence of okadaicacid resulted in phosphorylation of Ser129 in aS and accelera-
tion of the PUFA-induced formation of soluble aS oligomers,
in comparison with the cells overexpressing chloramphenicol
acetyltransferase (CAT) (Fig. 5A). To assess possible roles of
phosphorylation of Ser129 in the PUFA-induced oligomeriza-
tion of aS, we analyzed the cells co-transfected with GRK5
and one of the aS deletion mutants. The levels of soluble aS
oligomers in the presence of ALA decreased in the cells
expressing DN-aS or D20–60-aS, as compared with the cells
expressing Wt-aS or DM-aS (Fig. 5B). When measured relative
ratio of the band intensity of oligomers to that of monomers,
the formation of soluble oligomers of DN-aS or D20–60-aS in
the presence of ALA was much less than that of Wt-aS
(Fig. 5C).
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linked mutations
We investigated whether aS with familial PD-linked muta-
tions facilitates the PUFA-induced oligomerization using the
cells transfected with one of the familial PD-linked aS mu-
tants. The levels of soluble aS oligomers in the presence of
ALA were comparable in the cells expressing either E46K-
aS, A53T-aS, or Wt-aS (Fig. 6A and B). However, the cells
expressing A30P-aS failed to form soluble oligomers of the
mutant aS in the presence of ALA (Fig. 6A and B).4. Discussion
The present study revealed that recombinant aS proteins
bound FA through the amino acid residues 2–60 of aS. Of di-
rect relevance to the result is the report that recombinant aS
binds phospholipids with acidic head groups through the ami-
no acid residues 1–102 of aS [25]. The N-terminal half of aS
consists of seven repeats with an 11-residue periodicity [26].
The 11-residue repeats are a hallmark of the primary structure
of apolipoproteins [27]. The 11-residue repeats of apolipopro-
teins are known to take the conformation of amphipathic a-he-
lix, which is essential for the binding to lipids [27]. As predicted
by the structural similarity of aS to apolipoproteins, the N-ter-
minus of aS is shown to form the amphipathic a-helix [26] and
bind acidic phospholipids through the amphipathic a-helix
[26]. Therefore, it seems that the amphipathic a-helix in the
N-terminus of aS is also required for the binding of aS to
FA as well as phospholipids. The deletion mutants of aS lack-
ing the residues 2–19 or 20–60 may disrupt the conformation
of the amphipathic a-helix in the N-terminus of aS, resulting
in the loss of aS binding to FA.
We also investigated whether the N-terminal region of aS is
required for the PUFA-induced oligomerization of aS, and
found that the aS mutants lacking the residues 2–19 or 20–
60 failed to form aS oligomers in the presence of PUFA. This
indicates that the N-terminal FA-binding region of aS is also
essential for the PUFA-induced oligomerization of the mole-
cules.
Recent biochemical study has shown that most of aS depos-
ited in LB was phosphorylated at Ser129 and that a small pro-
portion of the deposited aS was C-terminally truncated [28]. It
has also been reported that the C-terminal truncation
[10,15,29] or Ser129 phosphorylation [13,14] facilitates the for-
mation of aS oligomers and aggregates. In the present study,
we determined the eﬀect of the C-terminal truncation or
Ser129 phosphorylation on the PUFA-induced oligomeriza-
tion of aS, and found that both of the C-terminal modiﬁca-
tions of aS were able to accelerate the formation of aS
oligomers induced by PUFA. This accelerating eﬀect was abol-
ished by the deletion of the N-terminus of aS, suggesting that
the N-terminus of aS is indispensable for the PUFA-induced
oligomerization of aS and that the C-terminus may function
as a modiﬁer for the aS oligomerization.
In the present study, it was found that either the E46K or
A53T mutation of aS had no apparent eﬀect on the PUFA-in-
duced oligomerization of aS, as compared with wild-type aS.
However, the A30P mutant failed to form aS oligomers in
the presence of PUFA. The latter observation is in agreement
with the report that aS inclusions are not detectable in thetransgenic mice with the A30P mutation of the aS gene [30].
It has been reported that the A30P mutation may disrupt the
conformation of the N-terminal a-helix of aS, although the
E46K or A53T mutation may not [31]. The conformational
changes may explain why the A30P mutant lost the ability to
bind to PUFA in the present study.
Although the aS oligomerization induced by PUFA has
been emphasized to play a crucial role in the pathogenesis of
PD [18], the present observation suggests that the PUFA-in-
duced oligomerization of aS may not be essential for the path-
ogenesis, especially in the familial PD with A30P mutation of
the aS gene. Possible explanation for the neurotoxicity by this
mutant is that an impaired binding of the A30P mutant to the
phospholipids of the membranes [32,33] may lead to the accu-
mulation of this protein in the cytosol, and the excess accumu-
lation of aS in the cytosol may cause the formation of aS
oligomers and ﬁbrils in a PUFA-independent manner [11]. An-
other possibility is that the ability of aS to bind to the membra-
nous structures, such as synaptic vesicles and presynaptic
membrane, may be lost by this mutation [32,33], and this
may result in an impairment of synaptic function [34,35], even-
tually leading to neurodegeneration.
In conclusion, we revealed the importance of the N-terminus
of wild-type aS in the PUFA-induced oligomerization of aS.
This property of aS was lost by the A30P mutation of aS, sug-
gesting that the degeneration of dopaminergic neurons occurs
without the process of the PUFA-induced oligomerization of
aS in this form of familial PD. Further studies are needed to
clarify the mechanism for the oligomerization of aS into ﬁbrils
and toxic species of aS. It may provide a clue for the elucida-
tion of a novel therapeutic strategy for PD.
Acknowledgments: This work was supported in part by the 21st Cen-
tury Center of Excellence (COE) Program (F03), Japan (T.K.) and
supported by Grant-in-Aid for Scientiﬁc Research (C) (S.A.
#19590979).Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at doi:10.1016/j.febs-
let.2008.10.001.References
[1] Polymeropoulos, M.H. et al. (1997) Mutation in the alpha-
synuclein gene identiﬁed in families with Parkinsons disease.
Science 276, 2045–2047.
[2] Kruger, R. et al. (1998) Ala30Pro mutation in the gene encoding
alpha-synuclein in Parkinsons disease. Nat. Genet. 18, 106–108.
[3] Zarranz, J.J. et al. (2004) The new mutation, E46K, of alpha-
synuclein causes Parkinson and Lewy body dementia. Ann.
Neurol. 55, 164–173.
[4] Singleton, A.B. et al. (2003) Alpha-synuclein locus triplication
causes Parkinsons disease. Science 302, 841.
[5] Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q.,
Jakes, R. and Goedert, M. (1997) Alpha-synuclein in Lewy
bodies. Nature 388, 839–840.
[6] Conway, K.A., Harper, J.D. and Lansbury, P.T. (1998) Acceler-
ated in vitro ﬁbril formation by a mutant alpha-synuclein linked
to early-onset Parkinson disease. Nat. Med. 4, 1318–1320.
[7] Masliah, E. et al. (2000) Dopaminergic loss and inclusion body
formation in alpha-synuclein mice. Implications for neurodegen-
erative disorders. Science 287, 1265–1269.
3700 H. Karube et al. / FEBS Letters 582 (2008) 3693–3700[8] Giasson, B.I., Duda, J.E., Quinn, S.M., Zhang, B., Trojanowski,
J.Q. and Lee, V.M. (2002) Neuronal alpha-synucleinopathy with
severe movement disorder in mice expressing A53T human alpha-
synuclein. Neuron 34, 521–533.
[9] Lee, M.K. et al. (2002) Human alpha-synuclein-harboring famil-
ial Parkinsons disease-linked Ala-53 –> Thr mutation causes
neurodegenerative disease with alpha-synuclein aggregation in
transgenic mice. Proc. Natl. Acad. Sci. USA 99, 8968–8973.
[10] Periquet, M., Fulga, T., Myllykangas, L., Schlossmacher, M.G.
and Feany, M.B. (2007) Aggregated alpha-synuclein mediates
dopaminergic neurotoxicity in vivo. J. Neurosci. 27, 3338–3346.
[11] Lee, V.M. and Trojanowski, J.Q. (2006) Mechanisms of Parkin-
sons disease linked to pathological alpha-synuclein: new targets
for drug discovery. Neuron 52, 33–38.
[12] Paxinou, E. et al. (2001) Induction of alpha-synuclein aggrega-
tion by intracellular nitrative insult. J. Neurosci. 21, 8053–8061.
[13] Fujiwara, H. et al. (2002) Alpha-synuclein is phosphorylated in
synucleinopathy lesions. Nat. Cell. Biol. 4, 160–164.
[14] Arawaka, S. et al. (2006) The role of G-protein-coupled receptor
kinase 5 in pathogenesis of sporadic Parkinsons disease. J.
Neurosci. 26, 9227–9238.
[15] Crowther, R.A., Jakes, R., Spillantini, M.G. and Goedert, M.
(1998) Synthetic ﬁlaments assembled from C-terminally truncated
alpha-synuclein. FEBS Lett. 436, 309–312.
[16] Perrin, R.J., Woods, W.S., Clayton, D.F. and George, J.M.
(2001) Exposure to long chain polyunsaturated fatty acids triggers
rapid multimerization of synucleins. J. Biol. Chem. 276, 41958–
41962.
[17] Sharon, R., Goldberg, M.S., Bar-Josef, I., Betensky, R.A., Shen,
J. and Selkoe, D.J. (2001) Alpha-synuclein occurs in lipid-rich
high molecular weight complexes, binds fatty acids, and shows
homology to the fatty acid-binding proteins. Proc. Natl. Acad.
Sci. USA 98, 9110–9115.
[18] Sharon, R., Bar-Joseph, I., Frosch, M.P., Walsh, D.M., Hamil-
ton, J.A. and Selkoe, D.J. (2003) The formation of highly soluble
oligomers of alpha-synuclein is regulated by fatty acids and
enhanced in Parkinsons disease. Neuron 37, 583–595.
[19] Glatz, J.F. and Veerkamp, J.H. (1983) A radiochemical procedure
for the assay of fatty acid binding by proteins. Anal. Biochem.
132, 89–95.
[20] Perrin, R.J., Payton, J.E., Barnett, D.H., Wraight, C.L., Woods,
W.S., Ye, L. and George, J.M. (2003) Epitope mapping and
speciﬁcity of the anti-alpha-synuclein monoclonal antibody Syn-1
inmouse brain and cultured cell lines. Neurosci. Lett. 349, 133–135.
[21] Jakes, R., Crowther, R.A., Lee, V.M., Trojanowski, J.Q.,
Iwatsubo, T. and Goedert, M. (1999) Epitope mapping of
LB509, a monoclonal antibody directed against human alpha-
synuclein. Neurosci. Lett. 269, 13–16.
[22] Giasson, B.I., Jakes, R., Goedert, M., Duda, J.E., Leight, S.,
Trojanowski, J.Q. and Lee, V.M. (2000) A panel of epitope-speciﬁc antibodies detects protein domains distributed throughout
human alpha-synuclein in Lewy bodies of Parkinsons disease. J.
Neurosci. Res. 59, 528–533.
[23] Saito, Y. et al. (2003) Accumulation of phosphorylated alpha-
synuclein in aging human brain. J. Neuropathol. Exp. Neurol. 62,
644–654.
[24] Kahle, P.J. et al. (2001) Selective insolubility of alpha-synuclein
in human Lewy body diseases is recapitulated in a transgenic
mouse model. Am. J. Pathol. 159, 2215–2225.
[25] Perrin, R.J., Woods, W.S., Clayton, D.F. and George, J.M.
(2000) Interaction of human alpha-synuclein and Parkinsons
disease variants with phospholipids. Structural analysis using site-
directed mutagenesis. J. Biol. Chem. 275, 34393–34398.
[26] Davidson, W.S., Jonas, A., Clayton, D.F. and George, J.M.
(1998) Stabilization of alpha-synuclein secondary structure upon
binding to synthetic membranes. J. Biol. Chem. 273, 9443–9449.
[27] Segrest, J.P., Jones, M.K., De Loof, H., Brouillette, C.G.,
Venkatachalapathi, Y.V. and Anantharamaiah, G.M. (1992)
The amphipathic helix in the exchangeable apolipoproteins: a
review of secondary structure and function. J. Lipid Res. 33, 141–
166.
[28] Anderson, J.P. et al. (2006) Phosphorylation of Ser-129 is the
dominant pathological modiﬁcation of alpha-synuclein in familial
and sporadic Lewy body disease. J. Biol. Chem. 281, 29739–
29752.
[29] Tofaris, G.K. et al. (2006) Pathological changes in dopaminergic
nerve cells of the substantia nigra and olfactory bulb in mice
transgenic for truncated human alpha-synuclein(1–120): implica-
tions for Lewy body disorders. J. Neurosci. 26, 3942–3950.
[30] Yavich, L. et al. (2005) Locomotor activity and evoked dopamine
release are reduced in mice overexpressing A30P-mutated human
alpha-synuclein. Neurobiol. Dis. 20, 303–313.
[31] Chandra, S., Chen, X., Rizo, J., Jahn, R. and Sudhof, T.C. (2003)
A broken alpha-helix in folded alpha-synuclein. J. Biol. Chem.
278, 15313–15318.
[32] Jensen, P.H., Nielsen, M.S., Jakes, R., Dotti, C.G. and Goedert,
M. (1998) Binding of alpha-synuclein to brain vesicles is abolished
by familial Parkinsons disease mutation. J. Biol. Chem. 273,
26292–26294.
[33] Jo, E., Fuller, N., Rand, R.P., St. George-Hyslop, P. and Fraser,
P.E. (2002) Defective membrane interactions of familial Parkin-
sons disease mutant A30P alpha-synuclein. J. Mol. Biol. 315,
799–807.
[34] Clayton, D.F. and George, J.M. (1998) The synucleins: a family
of proteins involved in synaptic function, plasticity, neurodegen-
eration and disease. Trends Neurosci. 21, 249–254.
[35] Larsen, K.E. et al. (2006) Alpha-synuclein overexpression in
PC12 and chromaﬃn cells impairs catecholamine release by
interfering with a late step in exocytosis. J. Neurosci. 26, 11915–
11922.
